Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016
Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Read more
Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies
Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and Company SHANGHAI, China, May 26, 2020…
Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19 SHANGHAI and INDIANAPOLIS, May 04,…
Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab
Combination with Pfizer’s Axitinib for the Treatment of Mucosal Melanoma SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences…
IND for Junshi Biosciences’ FIH anti-BTLA antibody approved by FDA
Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.